nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2D6—Parkinson's disease	0.461	0.583	CbGaD
Levomilnacipran—ABCB1—Parkinson's disease	0.329	0.417	CbGaD
Levomilnacipran—SLC6A2—locus ceruleus—Parkinson's disease	0.0107	0.146	CbGeAlD
Levomilnacipran—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00843	0.116	CbGeAlD
Levomilnacipran—SLC6A2—autonomic nervous system—Parkinson's disease	0.00567	0.0778	CbGeAlD
Levomilnacipran—SLC6A2—nerve—Parkinson's disease	0.00319	0.0438	CbGeAlD
Levomilnacipran—Diethylpropion—SLC6A3—Parkinson's disease	0.0028	0.371	CrCbGaD
Levomilnacipran—CYP2J2—forebrain—Parkinson's disease	0.00278	0.0382	CbGeAlD
Levomilnacipran—Pethidine—GRIN2B—Parkinson's disease	0.00276	0.366	CrCbGaD
Levomilnacipran—SLC6A4—hindbrain—Parkinson's disease	0.00271	0.0372	CbGeAlD
Levomilnacipran—CYP2J2—cardiovascular system—Parkinson's disease	0.00235	0.0323	CbGeAlD
Levomilnacipran—CYP2J2—medulla oblongata—Parkinson's disease	0.00201	0.0276	CbGeAlD
Levomilnacipran—CYP2J2—midbrain—Parkinson's disease	0.00184	0.0252	CbGeAlD
Levomilnacipran—CYP2J2—spinal cord—Parkinson's disease	0.00179	0.0246	CbGeAlD
Levomilnacipran—CYP2J2—head—Parkinson's disease	0.00159	0.0219	CbGeAlD
Levomilnacipran—SLC6A4—brainstem—Parkinson's disease	0.00155	0.0213	CbGeAlD
Levomilnacipran—CYP2J2—nervous system—Parkinson's disease	0.00151	0.0207	CbGeAlD
Levomilnacipran—SLC6A4—forebrain—Parkinson's disease	0.0015	0.0206	CbGeAlD
Levomilnacipran—CYP2J2—central nervous system—Parkinson's disease	0.00145	0.02	CbGeAlD
Levomilnacipran—CYP2J2—cerebellum—Parkinson's disease	0.00142	0.0195	CbGeAlD
Levomilnacipran—SLC6A2—brainstem—Parkinson's disease	0.00137	0.0188	CbGeAlD
Levomilnacipran—SLC6A2—forebrain—Parkinson's disease	0.00132	0.0181	CbGeAlD
Levomilnacipran—CYP2D6—hindbrain—Parkinson's disease	0.00131	0.018	CbGeAlD
Levomilnacipran—Pethidine—SLC6A3—Parkinson's disease	0.0013	0.173	CrCbGaD
Levomilnacipran—CYP2J2—brain—Parkinson's disease	0.00115	0.0159	CbGeAlD
Levomilnacipran—SLC6A4—midbrain—Parkinson's disease	0.00099	0.0136	CbGeAlD
Levomilnacipran—SLC6A4—spinal cord—Parkinson's disease	0.000966	0.0133	CbGeAlD
Levomilnacipran—SLC6A2—medulla oblongata—Parkinson's disease	0.000954	0.0131	CbGeAlD
Levomilnacipran—SLC6A4—head—Parkinson's disease	0.000859	0.0118	CbGeAlD
Levomilnacipran—SLC6A4—nervous system—Parkinson's disease	0.000814	0.0112	CbGeAlD
Levomilnacipran—SLC6A4—central nervous system—Parkinson's disease	0.000784	0.0108	CbGeAlD
Levomilnacipran—SLC6A2—head—Parkinson's disease	0.000756	0.0104	CbGeAlD
Levomilnacipran—CYP2D6—brainstem—Parkinson's disease	0.000749	0.0103	CbGeAlD
Levomilnacipran—CYP2D6—forebrain—Parkinson's disease	0.000723	0.00993	CbGeAlD
Levomilnacipran—SLC6A2—nervous system—Parkinson's disease	0.000717	0.00985	CbGeAlD
Levomilnacipran—SLC6A2—central nervous system—Parkinson's disease	0.00069	0.00948	CbGeAlD
Levomilnacipran—Pethidine—CYP2D6—Parkinson's disease	0.000685	0.0908	CrCbGaD
Levomilnacipran—SLC6A4—brain—Parkinson's disease	0.000622	0.00855	CbGeAlD
Levomilnacipran—ABCB1—embryo—Parkinson's disease	0.000588	0.00808	CbGeAlD
Levomilnacipran—SLC6A2—brain—Parkinson's disease	0.000548	0.00753	CbGeAlD
Levomilnacipran—ABCB1—forebrain—Parkinson's disease	0.00052	0.00714	CbGeAlD
Levomilnacipran—CYP2C8—brain—Parkinson's disease	0.00045	0.00618	CbGeAlD
Levomilnacipran—ABCB1—cardiovascular system—Parkinson's disease	0.00044	0.00604	CbGeAlD
Levomilnacipran—CYP2D6—head—Parkinson's disease	0.000414	0.00569	CbGeAlD
Levomilnacipran—CYP3A4—nervous system—Parkinson's disease	0.000399	0.00548	CbGeAlD
Levomilnacipran—CYP2D6—nervous system—Parkinson's disease	0.000393	0.00539	CbGeAlD
Levomilnacipran—CYP3A4—central nervous system—Parkinson's disease	0.000384	0.00527	CbGeAlD
Levomilnacipran—CYP2D6—central nervous system—Parkinson's disease	0.000378	0.00519	CbGeAlD
Levomilnacipran—ABCB1—medulla oblongata—Parkinson's disease	0.000376	0.00516	CbGeAlD
Levomilnacipran—CYP2D6—cerebellum—Parkinson's disease	0.000369	0.00507	CbGeAlD
Levomilnacipran—ABCB1—midbrain—Parkinson's disease	0.000343	0.00472	CbGeAlD
Levomilnacipran—ABCB1—spinal cord—Parkinson's disease	0.000335	0.0046	CbGeAlD
Levomilnacipran—CYP2D6—brain—Parkinson's disease	0.0003	0.00412	CbGeAlD
Levomilnacipran—ABCB1—head—Parkinson's disease	0.000298	0.00409	CbGeAlD
Levomilnacipran—ABCB1—nervous system—Parkinson's disease	0.000282	0.00388	CbGeAlD
Levomilnacipran—ABCB1—central nervous system—Parkinson's disease	0.000272	0.00373	CbGeAlD
Levomilnacipran—ABCB1—cerebellum—Parkinson's disease	0.000266	0.00365	CbGeAlD
Levomilnacipran—ABCB1—brain—Parkinson's disease	0.000216	0.00296	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	0.000134	0.00104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.000133	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP2D6—Parkinson's disease	0.000132	0.00102	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.00013	0.001	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	0.000129	0.001	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—Parkinson's disease	0.000129	0.000996	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PLA2G6—Parkinson's disease	0.000122	0.000948	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.000122	0.000941	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MAOB—Parkinson's disease	0.000121	0.000939	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP2E1—Parkinson's disease	0.00012	0.000931	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	0.000119	0.000921	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CP—Parkinson's disease	0.000119	0.00092	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	0.000119	0.000919	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000119	0.000919	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP2D6—Parkinson's disease	0.000117	0.000909	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.000116	0.000896	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	0.000115	0.000893	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GBA—Parkinson's disease	0.00011	0.000852	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP2E1—Parkinson's disease	0.000107	0.000831	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TRPM7—Parkinson's disease	0.000107	0.00083	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP1A3—Parkinson's disease	0.000107	0.00083	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	0.000107	0.000825	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000106	0.00082	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	0.000105	0.000814	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.0001	0.000774	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—COMT—Parkinson's disease	9.97e-05	0.000772	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTP1—Parkinson's disease	9.92e-05	0.000768	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—MAOA—Parkinson's disease	9.9e-05	0.000766	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	9.87e-05	0.000765	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—COMT—Parkinson's disease	9.83e-05	0.000761	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GBA—Parkinson's disease	9.82e-05	0.00076	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTP1—Parkinson's disease	9.78e-05	0.000758	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	9.74e-05	0.000754	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	9.5e-05	0.000735	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTM1—Parkinson's disease	9.12e-05	0.000706	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP2D6—Parkinson's disease	9.01e-05	0.000698	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTM1—Parkinson's disease	8.99e-05	0.000696	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—MAPK8—Parkinson's disease	8.9e-05	0.00069	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—COMT—Parkinson's disease	8.9e-05	0.000689	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTP1—Parkinson's disease	8.85e-05	0.000686	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CTGF—Parkinson's disease	8.84e-05	0.000685	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—MAOA—Parkinson's disease	8.83e-05	0.000684	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—COMT—Parkinson's disease	8.77e-05	0.000679	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTP1—Parkinson's disease	8.73e-05	0.000676	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—Parkinson's disease	8.63e-05	0.000668	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	8.47e-05	0.000656	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP2E1—Parkinson's disease	8.24e-05	0.000638	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—COMT—Parkinson's disease	8.18e-05	0.000634	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NQO1—Parkinson's disease	8.15e-05	0.000631	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	8.14e-05	0.000631	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTM1—Parkinson's disease	8.14e-05	0.00063	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	8.13e-05	0.00063	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	8.12e-05	0.000629	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	8.07e-05	0.000625	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	8.03e-05	0.000622	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TH—Parkinson's disease	8.03e-05	0.000622	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTM1—Parkinson's disease	8.02e-05	0.000621	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—Parkinson's disease	7.77e-05	0.000601	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL1B—Parkinson's disease	7.76e-05	0.000601	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CASP3—Parkinson's disease	7.74e-05	0.0006	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYCS—Parkinson's disease	7.71e-05	0.000597	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—Parkinson's disease	7.65e-05	0.000592	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	7.48e-05	0.000579	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	7.38e-05	0.000572	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	7.07e-05	0.000547	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	7.06e-05	0.000547	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—Parkinson's disease	6.96e-05	0.000539	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	6.96e-05	0.000539	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	6.86e-05	0.000532	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—COMT—Parkinson's disease	6.83e-05	0.000529	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTP1—Parkinson's disease	6.8e-05	0.000526	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Parkinson's disease	6.79e-05	0.000526	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	6.78e-05	0.000525	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MAOA—Parkinson's disease	6.78e-05	0.000525	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—HMOX1—Parkinson's disease	6.7e-05	0.000519	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ND3—Parkinson's disease	6.46e-05	0.0005	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MCCC1—Parkinson's disease	6.46e-05	0.0005	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	6.46e-05	0.0005	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ABCB1—Parkinson's disease	6.43e-05	0.000498	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	6.37e-05	0.000493	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—Parkinson's disease	6.24e-05	0.000484	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	6.13e-05	0.000474	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—OMD—Parkinson's disease	6.08e-05	0.000471	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TALDO1—Parkinson's disease	6.08e-05	0.000471	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GPX1—Parkinson's disease	5.98e-05	0.000463	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ND3—Parkinson's disease	5.77e-05	0.000447	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MCCC1—Parkinson's disease	5.77e-05	0.000447	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NDUFB11—Parkinson's disease	5.76e-05	0.000446	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—Parkinson's disease	5.69e-05	0.00044	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	5.69e-05	0.00044	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—Parkinson's disease	5.63e-05	0.000436	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ND3—Parkinson's disease	5.63e-05	0.000436	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MCCC1—Parkinson's disease	5.63e-05	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—Parkinson's disease	5.52e-05	0.000427	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GCH1—Parkinson's disease	5.5e-05	0.000426	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—OMD—Parkinson's disease	5.42e-05	0.00042	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TALDO1—Parkinson's disease	5.42e-05	0.00042	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—COMT—Parkinson's disease	5.35e-05	0.000414	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	5.32e-05	0.000412	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	5.31e-05	0.000411	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ND3—Parkinson's disease	5.31e-05	0.000411	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MCCC1—Parkinson's disease	5.31e-05	0.000411	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TALDO1—Parkinson's disease	5.29e-05	0.00041	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—OMD—Parkinson's disease	5.29e-05	0.00041	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	5.28e-05	0.000409	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	5.25e-05	0.000407	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CP—Parkinson's disease	5.23e-05	0.000405	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NDUFB11—Parkinson's disease	5.14e-05	0.000398	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—APOE—Parkinson's disease	5.14e-05	0.000398	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NDUFB11—Parkinson's disease	5.02e-05	0.000389	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—OMD—Parkinson's disease	4.99e-05	0.000386	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TALDO1—Parkinson's disease	4.99e-05	0.000386	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	4.96e-05	0.000384	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GCH1—Parkinson's disease	4.91e-05	0.00038	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GBA—Parkinson's disease	4.9e-05	0.000379	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DBH—Parkinson's disease	4.9e-05	0.000379	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FBP1—Parkinson's disease	4.9e-05	0.000379	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	4.89e-05	0.000379	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	4.83e-05	0.000374	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GCH1—Parkinson's disease	4.79e-05	0.000371	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	4.73e-05	0.000366	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GCH1—Parkinson's disease	4.51e-05	0.000349	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	4.42e-05	0.000343	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—INS—Parkinson's disease	4.39e-05	0.00034	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DBH—Parkinson's disease	4.37e-05	0.000339	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GBA—Parkinson's disease	4.37e-05	0.000339	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FBP1—Parkinson's disease	4.37e-05	0.000339	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GBA—Parkinson's disease	4.27e-05	0.00033	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FBP1—Parkinson's disease	4.27e-05	0.00033	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DBH—Parkinson's disease	4.27e-05	0.00033	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DBH—Parkinson's disease	4.02e-05	0.000311	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FBP1—Parkinson's disease	4.02e-05	0.000311	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GBA—Parkinson's disease	4.02e-05	0.000311	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	3.82e-05	0.000296	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.73e-05	0.000289	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DDC—Parkinson's disease	3.6e-05	0.000278	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.58e-05	0.000277	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	3.51e-05	0.000272	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.47e-05	0.000269	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ND3—Parkinson's disease	3.47e-05	0.000269	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTA4—Parkinson's disease	3.4e-05	0.000263	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	3.35e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.26e-05	0.000253	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—OMD—Parkinson's disease	3.26e-05	0.000253	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DDC—Parkinson's disease	3.21e-05	0.000248	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DDC—Parkinson's disease	3.13e-05	0.000243	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.11e-05	0.000241	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.09e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G6—Parkinson's disease	3.06e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTA4—Parkinson's disease	3.03e-05	0.000235	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MAOB—Parkinson's disease	3.03e-05	0.000234	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	2.99e-05	0.000232	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTA4—Parkinson's disease	2.96e-05	0.000229	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DDC—Parkinson's disease	2.95e-05	0.000229	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GCH1—Parkinson's disease	2.95e-05	0.000228	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.88e-05	0.000223	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTA4—Parkinson's disease	2.79e-05	0.000216	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	2.78e-05	0.000215	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G6—Parkinson's disease	2.73e-05	0.000211	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MAOB—Parkinson's disease	2.7e-05	0.000209	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G6—Parkinson's disease	2.66e-05	0.000206	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MAOB—Parkinson's disease	2.64e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DBH—Parkinson's disease	2.63e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.63e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GBA—Parkinson's disease	2.63e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.57e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	2.51e-05	0.000194	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MAOB—Parkinson's disease	2.48e-05	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	2.25e-05	0.000174	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CTGF—Parkinson's disease	2.21e-05	0.000171	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	2.06e-05	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NQO1—Parkinson's disease	2.03e-05	0.000157	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2D6—Parkinson's disease	2.01e-05	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TH—Parkinson's disease	2e-05	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CTGF—Parkinson's disease	1.97e-05	0.000153	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2D6—Parkinson's disease	1.96e-05	0.000152	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DDC—Parkinson's disease	1.93e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYCS—Parkinson's disease	1.92e-05	0.000149	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CTGF—Parkinson's disease	1.92e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2E1—Parkinson's disease	1.84e-05	0.000142	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.82e-05	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NQO1—Parkinson's disease	1.82e-05	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CTGF—Parkinson's disease	1.81e-05	0.00014	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2E1—Parkinson's disease	1.79e-05	0.000139	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TH—Parkinson's disease	1.79e-05	0.000139	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NQO1—Parkinson's disease	1.77e-05	0.000137	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TH—Parkinson's disease	1.75e-05	0.000135	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYCS—Parkinson's disease	1.72e-05	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—COMT—Parkinson's disease	1.7e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—Parkinson's disease	1.7e-05	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MAOA—Parkinson's disease	1.69e-05	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.69e-05	0.000131	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYCS—Parkinson's disease	1.68e-05	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—Parkinson's disease	1.67e-05	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.67e-05	0.000129	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TH—Parkinson's disease	1.65e-05	0.000127	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.64e-05	0.000127	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.62e-05	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—Parkinson's disease	1.61e-05	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.58e-05	0.000122	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—Parkinson's disease	1.56e-05	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—COMT—Parkinson's disease	1.52e-05	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—Parkinson's disease	1.51e-05	0.000117	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MAOA—Parkinson's disease	1.51e-05	0.000117	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—Parkinson's disease	1.49e-05	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—Parkinson's disease	1.49e-05	0.000116	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—COMT—Parkinson's disease	1.48e-05	0.000115	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.48e-05	0.000114	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MAOA—Parkinson's disease	1.47e-05	0.000114	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.46e-05	0.000113	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—Parkinson's disease	1.43e-05	0.000111	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—COMT—Parkinson's disease	1.4e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.37e-05	0.000106	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.36e-05	0.000105	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—Parkinson's disease	1.33e-05	0.000103	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.32e-05	0.000102	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—Parkinson's disease	1.3e-05	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—Parkinson's disease	1.28e-05	9.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.28e-05	9.91e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—Parkinson's disease	1.23e-05	9.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.23e-05	9.49e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.21e-05	9.35e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.2e-05	9.29e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.18e-05	9.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—Parkinson's disease	1.14e-05	8.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.13e-05	8.76e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—Parkinson's disease	1.12e-05	8.65e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.1e-05	8.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—INS—Parkinson's disease	1.1e-05	8.48e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.09e-05	8.45e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TH—Parkinson's disease	1.08e-05	8.33e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—Parkinson's disease	1.05e-05	8.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.03e-05	8e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—INS—Parkinson's disease	9.78e-06	7.57e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—INS—Parkinson's disease	9.55e-06	7.39e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—COMT—Parkinson's disease	9.15e-06	7.08e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—Parkinson's disease	9.11e-06	7.05e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MAOA—Parkinson's disease	9.08e-06	7.03e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—INS—Parkinson's disease	9e-06	6.97e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—Parkinson's disease	8.98e-06	6.95e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.62e-06	6.67e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—Parkinson's disease	8.37e-06	6.48e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—Parkinson's disease	8.01e-06	6.2e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—Parkinson's disease	7.39e-06	5.73e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—Parkinson's disease	6.88e-06	5.33e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—INS—Parkinson's disease	5.88e-06	4.55e-05	CbGpPWpGaD
